S&P 500   3,846.83 (-0.16%)
DOW   31,086.12 (-0.29%)
QQQ   325.27 (-0.33%)
AAPL   137.82 (+0.69%)
MSFT   227.34 (+1.05%)
FB   275.43 (+0.94%)
GOOGL   1,894.68 (+0.56%)
AMZN   3,289.95 (-0.52%)
TSLA   835.95 (-1.07%)
NVDA   549.05 (-1.02%)
BABA   258.71 (-0.50%)
CGC   33.35 (-0.63%)
GE   11.09 (+0.18%)
MU   82.68 (-2.74%)
AMD   92.82 (+1.41%)
NIO   60.98 (+4.53%)
T   28.88 (+0.17%)
F   11.46 (-0.61%)
ACB   10.38 (-7.07%)
BA   204.91 (-1.21%)
DIS   173.07 (+1.05%)
NFLX   570.81 (-1.56%)
GILD   67.18 (+0.30%)
S&P 500   3,846.83 (-0.16%)
DOW   31,086.12 (-0.29%)
QQQ   325.27 (-0.33%)
AAPL   137.82 (+0.69%)
MSFT   227.34 (+1.05%)
FB   275.43 (+0.94%)
GOOGL   1,894.68 (+0.56%)
AMZN   3,289.95 (-0.52%)
TSLA   835.95 (-1.07%)
NVDA   549.05 (-1.02%)
BABA   258.71 (-0.50%)
CGC   33.35 (-0.63%)
GE   11.09 (+0.18%)
MU   82.68 (-2.74%)
AMD   92.82 (+1.41%)
NIO   60.98 (+4.53%)
T   28.88 (+0.17%)
F   11.46 (-0.61%)
ACB   10.38 (-7.07%)
BA   204.91 (-1.21%)
DIS   173.07 (+1.05%)
NFLX   570.81 (-1.56%)
GILD   67.18 (+0.30%)
S&P 500   3,846.83 (-0.16%)
DOW   31,086.12 (-0.29%)
QQQ   325.27 (-0.33%)
AAPL   137.82 (+0.69%)
MSFT   227.34 (+1.05%)
FB   275.43 (+0.94%)
GOOGL   1,894.68 (+0.56%)
AMZN   3,289.95 (-0.52%)
TSLA   835.95 (-1.07%)
NVDA   549.05 (-1.02%)
BABA   258.71 (-0.50%)
CGC   33.35 (-0.63%)
GE   11.09 (+0.18%)
MU   82.68 (-2.74%)
AMD   92.82 (+1.41%)
NIO   60.98 (+4.53%)
T   28.88 (+0.17%)
F   11.46 (-0.61%)
ACB   10.38 (-7.07%)
BA   204.91 (-1.21%)
DIS   173.07 (+1.05%)
NFLX   570.81 (-1.56%)
GILD   67.18 (+0.30%)
S&P 500   3,846.83 (-0.16%)
DOW   31,086.12 (-0.29%)
QQQ   325.27 (-0.33%)
AAPL   137.82 (+0.69%)
MSFT   227.34 (+1.05%)
FB   275.43 (+0.94%)
GOOGL   1,894.68 (+0.56%)
AMZN   3,289.95 (-0.52%)
TSLA   835.95 (-1.07%)
NVDA   549.05 (-1.02%)
BABA   258.71 (-0.50%)
CGC   33.35 (-0.63%)
GE   11.09 (+0.18%)
MU   82.68 (-2.74%)
AMD   92.82 (+1.41%)
NIO   60.98 (+4.53%)
T   28.88 (+0.17%)
F   11.46 (-0.61%)
ACB   10.38 (-7.07%)
BA   204.91 (-1.21%)
DIS   173.07 (+1.05%)
NFLX   570.81 (-1.56%)
GILD   67.18 (+0.30%)
Log in
NASDAQ:HZNP

Horizon Therapeutics Public Stock Forecast, Price & News

$77.70
+0.27 (+0.35 %)
(As of 01/22/2021 01:10 PM ET)
Add
Compare
Today's Range
$75.83
Now: $77.70
$77.75
50-Day Range
$67.00
MA: $73.99
$81.20
52-Week Range
$23.81
Now: $77.70
$86.67
Volume23,071 shs
Average Volume1.91 million shs
Market Capitalization$17.15 billion
P/E Ratio21.23
Dividend YieldN/A
Beta1.15
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of rheumatoid arthritis (RA), polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and ankylosing spondylitis to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Horizon Therapeutics Public logo

MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

11th out of 1,921 stocks

Pharmaceutical Preparations Industry

5th out of 769 stocks

Analyst Opinion: 2.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 4.4 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:HZNP
CUSIP44047T10
Phone011-353-1772-2100
Employees1,200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.30 billion
Cash Flow$3.50 per share
Book Value$11.67 per share

Profitability

Net Income$573.02 million

Miscellaneous

Market Cap$17.15 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$77.70
+0.27 (+0.35 %)
(As of 01/22/2021 01:10 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HZNP News and Ratings via Email

Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Horizon Therapeutics Public (NASDAQ:HZNP) Frequently Asked Questions

How has Horizon Therapeutics Public's stock price been impacted by COVID-19 (Coronavirus)?

Horizon Therapeutics Public's stock was trading at $30.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HZNP stock has increased by 153.8% and is now trading at $77.43.
View which stocks have been most impacted by COVID-19
.

Is Horizon Therapeutics Public a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Horizon Therapeutics Public stock.
View analyst ratings for Horizon Therapeutics Public
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Horizon Therapeutics Public?

Wall Street analysts have given Horizon Therapeutics Public a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Horizon Therapeutics Public wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Horizon Therapeutics Public's CEO?

1,448 employees have rated Horizon Therapeutics Public CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Horizon Therapeutics Public's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Horizon Therapeutics Public's next earnings date?

Horizon Therapeutics Public is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Horizon Therapeutics Public
.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) issued its quarterly earnings data on Saturday, November, 7th. The biopharmaceutical company reported $1.74 EPS for the quarter, beating the Zacks' consensus estimate of $0.97 by $0.77. The biopharmaceutical company had revenue of $636.40 million for the quarter, compared to analysts' expectations of $531.11 million. Horizon Therapeutics Public had a return on equity of 25.66% and a net margin of 43.55%. Horizon Therapeutics Public's revenue was up 89.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.64 EPS.
View Horizon Therapeutics Public's earnings history
.

What guidance has Horizon Therapeutics Public issued on next quarter's earnings?

Horizon Therapeutics Public updated its FY 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.14 billion, compared to the consensus revenue estimate of $2.13 billion.

What price target have analysts set for HZNP?

8 Wall Street analysts have issued 12-month price objectives for Horizon Therapeutics Public's stock. Their forecasts range from $51.00 to $112.00. On average, they anticipate Horizon Therapeutics Public's stock price to reach $93.67 in the next twelve months. This suggests a possible upside of 21.0% from the stock's current price.
View analysts' price targets for Horizon Therapeutics Public
or view Wall Street analyst' top-rated stocks.

Are investors shorting Horizon Therapeutics Public?

Horizon Therapeutics Public saw a increase in short interest in December. As of December 31st, there was short interest totaling 8,910,000 shares, an increase of 28.0% from the December 15th total of 6,960,000 shares. Based on an average trading volume of 2,650,000 shares, the days-to-cover ratio is presently 3.4 days.
View Horizon Therapeutics Public's Short Interest
.

Who are some of Horizon Therapeutics Public's key competitors?

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

Who are Horizon Therapeutics Public's key executives?

Horizon Therapeutics Public's management team includes the following people:
  • Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 54, Pay $4.73M)
  • Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 56, Pay $1.67M)
  • Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 67, Pay $1.46M)
  • Mr. Vikram Karnani, Exec. VP & Pres of International (Age 46, Pay $1.34M)
  • Mr. Miles W. McHugh, Chief Accounting Officer & Sr. VP (Age 56)
  • Dr. Karin Rosen M.D., Ph.D., Exec. VP of R&D and Chief Scientific Officer
  • Ms. Tina E. Ventura, Sr. VP of Investor Relations
  • Mr. Brian K. Beeler, Exec. VP & Gen. Counsel (Age 48)
  • Mr. Timothy Ayers, Chief Compliance Officer & VP
  • Mr. Geoffrey M. Curtis, Exec. VP of Corp. Affairs & Chief Communications Officer (Age 46)

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Frontier Capital Management Co. LLC (0.50%), Scout Investments Inc. (0.44%), Columbus Circle Investors (0.36%), AMI Asset Management Corp (0.32%), Rhenman & Partners Asset Management AB (0.27%) and Deltec Asset Management LLC (0.07%). Company insiders that own Horizon Therapeutics Public stock include Barry Moze, Brian K Beeler, Daniel A Camardo, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert and Vikram Karnani.
View institutional ownership trends for Horizon Therapeutics Public
.

Which major investors are selling Horizon Therapeutics Public stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Columbus Circle Investors, Rhenman & Partners Asset Management AB, AMI Asset Management Corp, Sowell Financial Services LLC, First Hawaiian Bank, Highland Capital Management LLC, and Tributary Capital Management LLC. Company insiders that have sold Horizon Therapeutics Public company stock in the last year include Barry Moze, Brian K Beeler, Daniel A Camardo, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, and Vikram Karnani.
View insider buying and selling activity for Horizon Therapeutics Public
or view top insider-selling stocks.

Which major investors are buying Horizon Therapeutics Public stock?

HZNP stock was purchased by a variety of institutional investors in the last quarter, including Scout Investments Inc., Deltec Asset Management LLC, Kestra Advisory Services LLC, Redpoint Investment Management Pty Ltd, Vigilare Wealth Management, Park Avenue Securities LLC, Exchange Traded Concepts LLC, and State of Alaska Department of Revenue.
View insider buying and selling activity for Horizon Therapeutics Public
or or view top insider-buying stocks.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $77.43.

How big of a company is Horizon Therapeutics Public?

Horizon Therapeutics Public has a market capitalization of $17.09 billion and generates $1.30 billion in revenue each year. The biopharmaceutical company earns $573.02 million in net income (profit) each year or $1.94 on an earnings per share basis. Horizon Therapeutics Public employs 1,200 workers across the globe.

What is Horizon Therapeutics Public's official website?

The official website for Horizon Therapeutics Public is www.horizontherapeutics.com.

How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.